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Abstract 
Background: Malaria causes significant morbidity in Malawi, with an estimated 5 million cases in 2014. Artemether-
lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first- and second-line treatments for uncomplicated 
malaria, respectively, but emerging resistance threatens their efficacy. In order to understand whether AL and ASAQ 
remain efficacious for the treatment of uncomplicated Plasmodium falciparum malaria in Malawi, a therapeutic effi-
cacy trial was conducted.
Methods: During March–July 2014, febrile children aged 6–59 months with microscopy-confirmed uncomplicated 
P. falciparum malaria (1000–200,000 parasites/μL) were enrolled in a 28-day randomized in vivo efficacy trial at three 
sites: one each in northern (Karonga), central (Nkhotakota) and southern (Machinga) Malawi. The study was powered 
to estimate site-specific efficacy for AL and overall efficacy for ASAQ, with 3:1 randomization to AL or ASAQ. Blood was 
collected for malaria microscopy and molecular testing on days 0–3, 7, 14, 21, and 28. Recrudescence and reinfec-
tion were differentiated using polymerase chain reaction (PCR) genotyping of merozoite surface protein. The primary 
outcome was the PCR-corrected day 28 Kaplan–Meier cumulative success rate.
Results: A total of 452 children were enrolled; 303/338 (89 %) and 98/114 (86 %) reached a study endpoint in AL and 
ASAQ arms, respectively. All treatment failures occurred after day 3. The day 28 uncorrected cumulative success rate 
was 97.1 % (95 % confidence interval [CI]: 93.9–100 %) for ASAQ and 76.8 % (95 % CI 72.1–81.5 %) for AL, with 82.5 % 
(95 % CI 75.4–89.7 %), 69 % (95 % CI 59.9–78.1 %), and 78.2 % (95 % CI 70.2–86.3 %) success in the northern, central, 
and southern regions, respectively. The day 28 PCR-corrected cumulative success rate was 99 % (95 % CI 97.2–100 %) 
in the ASAQ arm and 99.3 % (95 % CI 98.3–100 %) in the AL arm, with 98–100 % efficacy in each site.
Conclusions: As evidenced by the day 28 PCR-corrected cumulative success rates, both AL and ASAQ remain effica-
cious treatments for uncomplicated malaria in Malawi. The lower uncorrected efficacy in the AL arm compared to 
ASAQ may be explained by the shorter half-life of lumefantrine (3–6 days) compared to amodiaquine (9–18 days). The 
high reinfection rate suggests that there is a continued need to scale-up effective malaria prevention interventions.
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Background
Malaria is a cause of considerable morbidity and mor-
tality in Malawi, with 5 million cases in 2014. The vast 
majority of these cases and deaths were caused by Plas-
modium falciparum [1]. Malaria prevalence among chil-
dren less than 5  years of age in 2014 was 29  % in the 
Northern Region, 33 % in the Southern Region, and 36 % 
in the Central Region [2]. Due to rising resistance to and 
falling efficacy of sulfadoxine–pyrimethamine, the first-
line treatment of uncomplicated malaria from 1993–
2007, the National Malaria Control Programme (NMCP) 
revised the national treatment guidelines in 2007 to rec-
ommend artemether-lumefantrine (AL) as the first-line 
treatment and artesunate-amodiaquine (ASAQ) as a sec-
ond-line treatment for uncomplicated malaria. Results 
from recent studies conducted in Malawi and surround-
ing countries suggest that AL remains efficacious for 
treatment of uncomplicated P. falciparum malaria [3–6].
In 2010, the overall efficacy of AL across six sites in 
Malawi was 93.4 % [3]. Studies conducted in the neigh-
bouring countries of Tanzania, Zambia, and Mozambique 
have reported efficacies from 96 to 100  % for both AL 
and ASAQ [4–6], suggesting that both regimens remain 
efficacious for treatment of uncomplicated malaria in this 
region. Given the potential for development of parasite 
resistance, it is imperative to continue to monitor the effi-
cacy of these regimens [7–9]. The World Health Organi-
zation (WHO) recommends routine monitoring of ACT 
efficacy using standardized in  vivo therapeutic efficacy 
studies and changing treatments when the efficacy of a 
regimen drops below 90 % [10]. In order to provide the 
Malawian Ministry of Health with updated estimates of 
treatment efficacy, a 28-day therapeutic efficacy study of 
AL and ASAQ for the treatment of uncomplicated P. fal-
ciparum malaria in children aged six to 59  months was 
conducted in three sites in Malawi.
Methods
Study timing and location
This study was conducted between March and July of 
2014 at three district-level hospitals: Karonga District 
Hospital in the northern region, Nkhotakota District 
Hospital in the central region, and Machinga District 
Hospital in the southern region. Malaria transmission is 
stable throughout the year with a peak in the rainy sea-
son, December to April.
Sample size
The minimum sample size needed to achieve a preci-
sion to detect 5 % failures, at a confidence level of 95 %, 
assuming a drug efficacy of 95 %, was 94 participants per 
arm. The target sample size was increased to 113 per arm 
to allow for approximately 15 % loss to follow up. As AL 
is the first-line treatment and widely used, the study was 
powered to provide regional estimates for AL efficacy 
and a country-wide estimate for ASAQ, resulting in a 
target sample size of 452 participants, 339 in the AL arm 
and 113 in the ASAQ arm.
Study procedures
The standard in  vivo WHO protocol was used [10]. 
Children aged 6–59  months presenting to participat-
ing hospitals with fever (axillary temperature ≥37.5  °C) 
or a history of fever in the past 24  h were screened for 
malaria using a rapid diagnostic test (RDT; Paracheck-
Pf®, Orchid Biomedical Systems, Goa, India). If the RDT 
was positive, two thick and one thin blood smears were 
obtained; an initial rapid reading of the thick smear was 
used to determine whether the patient met the eligibility 
criteria for parasitaemia, after enrollment the remaining 
smears were stained more carefully to obtain more accu-
rate parasite estimates and species. Children who were 
RDT-positive but ineligible for enrollment were treated 
with AL according to national guidelines. Children with 
microscopically detected P. falciparum mono-infection 
with 1000–200,000 asexual parasites/μl were eligible for 
enrollment provided that they were able to swallow oral 
medication, had no danger signs, including severe mal-
nutrition, reported no allergies to the study medications, 
were not taking any medications that could interfere with 
the study drugs, and the parents/guardians provided 
informed consent.
After enrollment, children were randomized 3:1 to 
receive either AL (20  mg artemether/120  mg lumefan-
trine per tablet, Coartem-D™; Novartis, Basel, Switzer-
land) or ASAQ (25 mg artesunate/67.5 mg amodiaquine 
or 50  mg artesunate/135  mg amodiaquine per tablet, 
Coarsucam™; Sanofi-Aventis, Paris, France). The ran-
domization list was generated for each site using per-
muted-block randomization in the R (version 3.2.0) 
blockrand package (R foundation for statistical comput-
ing, Vienna, Austria). Study staff in Malawi did not have 
access to this list. Cards with the treatment assignment 
were created based on the list and concealed in opaque 
envelopes that were opened at the time of first adminis-
tration. Treatment was directly administered with clean 
water following manufacturer’s prescribed weight-based 
dosing, twice daily for AL (5–14  kg: 1 tablet; 15–24: 2 
tablets; 25–34  kg: 3 tablets; >34  kg: 4 tablets per dose) 
and daily for ASAQ (4.5–8.9  kg: 1 25  mg/67.5  mg tab-
let; 9–17.9  kg: 1 50  mg/135  mg tablet; 18–35.9  kg: 2 
50  mg/135 tablets; >36  kg: 4 50  mg/135  mg tablets per 
dose) for 3 days. Participants were observed for 30 min 
after treatment to monitor for vomiting or other adverse 
events; those who vomited were administered a second 
dose and observed for an additional 30 min. Patients who 
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vomited both doses were removed from the study and 
referred to the hospital for parenteral treatment. Study 
staff directly observed all three ASAQ doses and all three 
morning AL doses. Parents or guardians were given the 
evening AL doses with instructions for administering the 
drug; parents were asked to verify administration at the 
visit the following day.
Patients were seen routinely on day 0 (enrollment), 
days 1, 2, 3, 7, 14, 21 and 28 [10], as well as on any other 
day when they felt ill. At each visit, a standard symp-
toms questionnaire and clinical exam was conducted and 
blood was collected for thick and thin smears and for 
molecular testing. On days 0, 14 and 28, additional blood 
was collected for haemoglobin (Hb) testing (Hemocue, 
Inc, Cypress, CA, USA). On D0 and D7, participants ran-
domized to ASAQ had blood drawn for aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT) 
levels.
Microscopic blood examination
At enrollment, two slides were obtained. The first slide 
(thick smear only) was stained rapidly, using 10 % Giemsa 
for 10–15  min, and parasitaemia counted to determine 
eligibility. In patients deemed eligible for enrollment, the 
second slide (thick and thin smears) was stained with 
2.5–3  % Giemsa for 45–60  min and re-read; the results 
from the second slide constituted the final enrollment 
parasitaemia. For all subsequent visits, only the slower 
stain methodology was used.
Two on-site microscopists independently read the 
smears according to WHO protocol, each was blinded to 
the other’s read [10]. If species were discordant or para-
sitaemia estimates differed by more than 50  % on final 
study review approximately 1 month after the study com-
pleted, slides were read by a third microscopist [10]. Par-
asites were counted against 200 white blood cells (WBCs) 
in the thick smear. A minimum of 100 fields were exam-
ined to exclude mixed infections; if a mixed infection 
could not be excluded based on thick smear, the thin 
smear was examined for confirmation. A total of 1000 
WBCs were counted in order to classify a smear as nega-
tive; a smear was negative if two microscopists identified 
it as negative. Parasitaemia was calculated by dividing the 
number of asexual parasites counted by the number of 
leukocytes counted, multiplied by an assumed average of 
8000 WBCs/μl blood. The final parasitaemia was the geo-
metric mean of the nearest two independent readings.
Study outcomes
Patients were classified according to the WHO defini-
tion of therapeutic responses [10]. Early treatment failure 
(ETF) was defined as having signs of severe malaria on 
days 1–3, with parasitaemia on day 2 higher than on day 
0 (irrespective of axillary temperature), parasitaemia on 
day 3 with axillary temperature ≥37.5 °C, or parasitaemia 
on day 3 ≥25 % of count on day 0. Late treatment failure 
was divided into two categories: late clinical failure (LCF) 
and late parasitologic failure (LPF). LCF was defined as 
danger signs or severe malaria in the presence of parasi-
taemia on any day between day 4 and day 28 in patients 
who did not previously meet any of the criteria of ETF 
or presence of parasitaemia on any day between day 4 
and day 28 with axillary temperature ≥37.5 °C or history 
of fever in patients who did not previously meet any of 
the criteria of early treatment failure. LPF was defined as 
presence of parasitaemia on any day between day 7 and 
day 28 and axillary temperature <37.5 °C in patients who 
did not previously meet any of the criteria for early treat-
ment failure or late clinical failure. Adequate clinical and 
parasitologic response (ACPR) was defined as absence of 
parasitaemia on day 28, irrespective of axillary tempera-
ture, in patients who did not previously meet any of the 
criteria of ETF, LCF, or LPF. Children who met criteria 
for ETF, LCF, or LPF were treated with the regimen to 
which they were not randomized and were removed from 
further study participation. Loss to follow-up occurred 
when, despite all reasonable efforts, enrolled patients did 
not attend the scheduled visits and could not be found 
or located. Every effort was made to schedule a follow-
up visit for patients who failed to return to the study site, 
especially during but also after administration of the 
study drug. Patients who missed day 1, 2, or 3, or missed 
more than one visit after day 3 were classified as lost to 
follow-up. No treatment outcome was assigned to these 
patients and their last day in the study was the last visit 
they attended.
Molecular testing
In order to differentiate between reinfection and recru-
descence, DNA samples extracted from paired dried 
blood spot samples from day 0 and the day of recur-
rence were subjected to nested PCR for two microsat-
ellite markers, merozoite surface protein 1 (msp1) and 
merozoite surface protein 2 (msp2), using WHO recom-
mended PCR procedures [10]. Differences in amplicon 
length were assessed on a 2 % agarose gel with day 0 and 
the day of recurrence samples run in adjacent lanes for 
ease of size comparison.
Statistical analysis
The primary efficacy endpoint was the day 28-PCR-
adjusted cure rate, estimated by Kaplan–Meier 
analysis. The uncorrected and PCR-corrected Kaplan–
Meier cumulative success rates on day 28 were 
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calculated among all participants with any follow-
up time; patients were censored when they reached 
a valid study endpoint, or were lost to follow-up or 
withdrawn. In addition, the uncorrected and PCR-
corrected ACPR on day 28 was calculated among only 
those participants who reached a valid study end-
point. Where sample sizes were sufficient, t-tests and 
ANOVA were used to compare means, Wilcoxon and 
Kruskal–Wallis tests to compare medians and Pear-
son’s Chi square to compare proportions. P-values less 
than 0.05 or non-overlapping 95  % confidence inter-
vals (CIs) were considered significant for all statisti-
cal tests. Greenwood’s formula was used to calculate 
95  % CIs for Kaplan–Meier cumulative success rates. 
All data analysis was done using SAS version 9.3 (SAS 
Institute, Carey, North Carolina).
Ethical considerations
Written, informed consent was obtained from the 
legal guardian of each study participant. This study was 
approved by the ethical review boards at the Centers for 
Disease Control and Prevention (CDC) in Atlanta, GA 
(protocol #6029) and the Malawi College of Medicine in 
Blantyre, Malawi (protocol #P.11/13/1486).
Results
A total of 1561 children were screened; 925 (59.7  %) 
were RDT positive and, of those, 452 (48.8) were 
enrolled (Fig.  1). Of those who were RDT positive but 
not enrolled, 31.3  % did not meet parasitaemia criteria, 
9.3 % were unwilling to comply with the study protocol 
or refused to participate, and the remaining 59.4 % were 
excluded due to inability to swallow oral medication, tak-
ing medication in the past 2  weeks with anti-malarial 
activity, allergy, or malnutrition. In the AL arm, 338 were 
enrolled, 332 (97.9 %) completed treatment as assigned, 
and 303 (89 %) reached a valid study endpoint (29 were 
lost to follow up). In the ASAQ arm, 114 were enrolled, 
110 (95.7  %) completed treatment as assigned, and 98 
(86 %) reached a valid study endpoint (12 were lost to fol-
low up).
Characteristics at enrollment were generally similar 
between both study arms (Table 1). Children randomized 
to AL were significantly younger and a higher propor-
tion were female compared to children randomized to 
ASAQ. Insecticide-treated bed net (ITN) use the previ-
ous night differed between sites, with 64.2 % of children 
sleeping under an ITN in Nkhotakota, 89.1 % in Karonga, 
and 91 % in Machinga. A lower proportion of children in 
1,561 screened
453 (48.8%) enrolled
AL arm ASAQ arm
338 participants
303 (89%) reached a study 
endpoint
114 participants
98 (86%) reached a study 
endpoint
925 (59.7%) RDT positive
1 enrollment violation; patient 
with severe malaria included, 
withdrawn after receipt of 
study drug on Day 0 
148 did not meet parasitemia 
criteria
44 refused to participate or 
comply with study protocol
280 excluded due to inability 
to swallow oral medication, 
current treatments with 
antimalarial activity, allergy, 
or malnutrition 
Fig. 1 Screening, enrollment, and follow-up of study participants in a therapeutic efficacy study in Machinga, Nkhotakota, and Karonga Districts, in 
Malawi, 2014
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Karonga had anaemia (69  %) compared to Nkhotakota 
(77  %) and Machinga (88.4  %) (p value <0.0001). Geo-
metric mean parasitaemia was 35,512 parasites/μL (range 
1100–394,400) in the AL arm and 30,882 parasites/μL 
(range 1019–274,908) in the ASAQ arm.
Treatment efficacy
There were no ETFs in either arm (Table  2). Only one 
participant remained parasitaemic on day 3. This partici-
pant was in the AL arm and had a day 3 parasitaemia of 
99.7 parasites/μL, 0.05 % of day 0 parasitaemia (198,000 
parasites/μL). In the uncorrected Kaplan–Meier cumu-
lative success rate analysis, most failures in the AL arm 
occurred on day 21 (Fig.  2) and 76.8  % (95  % CI 72.1–
81.5) of participants remained parasite free on day 28. 
Nkhotakota had the lowest percent of participants who 
remained parasite free on day 28 (69.0 %; 95 % CI 59.9–
78.1), followed by Machinga (78.2 %; 95 % CI 70.2–86.3), 
and Karonga (82.5 %; 95 % CI 75.4–89.7). In the ASAQ 
arm 99.0 % (95 % CI 97.2–100.0) of participants remained 
parasite free, with the first two failures observed on day 
14 (Fig.  2). Uncorrected ACPR results were similar to 
uncorrected Kaplan–Meier estimates. In the AL arm the 
uncorrected ACPR was 76.2 % (95 % CI 71–80.9) and in 
the ASAQ arm, the uncorrected ACPR was 96.9 % (95 % 
CI 94.5–100.0).
Using PCR-corrected data, of the 72 LTFs in partici-
pants randomized to AL, 70 were classified as reinfec-
tions and two as recrudescences. The median time to 
reinfection was 21  days (Fig.  2). One recrudescence 
occurred on day 14 and the other on day 28. Nkhotakota 
(31.6 %) had a significantly higher proportion of reinfec-
tions compared with Machinga (22.4  %) and Karonga 
(15.9  %). In the ASAQ arm, three LTFs occurred; two 
were reinfections that occurred on day 14 and 21, and 
one was a recrudescence that occurred on day 14 (Fig. 2). 
The PCR-corrected Kaplan–Meier cure rate was 99.3  % 
(95 % CI 98.3–100) and similar across sites in the AL arm 
and 99.0 % (95 % CI 97.2–100) in the ASAQ arm.
Of the 452 study participants, 26 (6.1  %) had parasi-
taemia greater than 200,000 parasites/μL. These partici-
pants were eligible for study inclusion based on the initial 
screening of the thick smear but were later found to have 
an enrollment parasitaemia higher than 200,000 para-
sites/μL according to a final study review. All analyses 
were performed both with (Tables 1 and 2) and without 
these participants (Tables 3 and 4); the results were not 
substantially different between the analyses.
Haemoglobin results
Of those randomized to AL, average Hb levels increased 
from 9.8  g/dL (95  % CI 9.5–10.0) measured on day 0 to 
10.12 g/dL (95 % CI 10.0–10.3) on day 14, reaching 10.8 g/
dL (95 % CI 10.6–11.0) by the last visit on day 28 (Fig. 3); 
this represented a significant increase in the mean Hb lev-
els between day 0 and day 28 (1.2 g/dL, SD 1.6, p < 0.0001). 
Average Hb levels among ASAQ patients also increased, 
from 10.0 g/dL (95 % CI 9.6–10.3) on day 0 to 10.4 g/dL 
(95 % CI 10.2–10.7) on day 14, with a mean value of 11.0 g/
dL (95 % CI 10.7–11.3) on day 28 (a 9.5 % compared to day 
Table 1 Participant characteristics at study enrollment in Machinga, Nkhotakota, and Karonga Districts, in Malawi, 2014 
(n = 452)
All participants were eligible for enrollment based on initial parasitaemia (1000–200,000 parasites/μL); however, 26 (6.1 %) participants had parasitaemia higher than 
200,000 parasites/μL according to slide reviews done after study completion
* Significant difference between study arms (p < 0.05); † significant difference between study sites (p < 0.05)












Age, months (median, range)*, † 31 (6, 58) 35 (7, 58) 27 (6, 57) 34 (6, 57) 38 (9, 59)
Male, n (%)* 176 (52.1) 67 (59.8) 49 (43.4) 60 (53.1) 45 (39.5)
Participant slept under ITN  
previous night, n (%)†, a
269 (81.5) 101 (91) 70 (64.2) 98 (89.1) 92 (84.4)
Weight (kg) (mean, SD)† 11.3 (3.6) 11.9 (3.1) 11.3 (2.2) 10.7 (4.8) 11.7 (3.4)
Haemoglobin (g/dL) (mean, SD)† 9.8 (2.3) 9.4 (3.2) 9.7 (1.8) 10.2 (1.5) 10.0 (1.9)
Anaemia (Hb ≤11.0 g/dL)† 264 (78.1) 99 (88.4) 87 (77) 78 (69) 84 (73.7)
Parasitaemia (parasites/μL)  
(geometric mean, range)†, b
35,512 (1100, 394,400) 25,700 (1100, 198,000) 39,171 (1393, 394,400) 44,361 (2066, 265,750) 30,882 (1019, 274,908)
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0); the mean difference in Hb levels between days 0 and 28 
was statistically significant (p < 0.0001). Mean differences 
in Hb levels between days 0 and 28 were not significantly 
different between study arms.
Safety and tolerability
Overall, both regimens were well tolerated. Seven 
patients in the AL arm reported non-compliance with the 
evening dose; three of these patients subsequently failed 
therapy. In the AL arm, 21 (6.2 %) of participants vomited 
at least one dose; four patients (1.2 %) vomited the repeat 
dose and were withdrawn. In the ASAQ arm, 12 (10.5 %) 
vomited at least one dose; 1 (0.9  %) vomited the repeat 
dose and were withdrawn. No significant differences in 
vomiting the first or second dose were found between 
study arms. All patients who vomited second doses of 
Table 2 Participant response to  treatment over  28-day follow-up among  participants in  a therapeutic efficacy study 
in Machinga, Nkhotakota, and Karonga Districts in Malawi, 2014 (n = 452)
* Significant difference between study sites (p < 0.05)
a Percent day 3 clearance was estimated only among participants still enrolled in the study on day 3
b Adequate clinical and parasitologic response (ACPR) was estimated only among participants who reached a valid study endpoint
c The Kaplan–Meier cumulative survival rate estimate included all study participants who contributed person-days during the 28-day follow-up
d For Kaplan–Meier cumulative survival rates of 100 %, confidence intervals were not estimated
Estimate AL ASAQ
Total (n = 338) Site Total (n = 114)
Machinga (n = 112) Nkhotakota (n = 113) Karonga (n = 113)
Participants lost to follow-up, n (%) 35 (10.4) 14 (12.5) 15 (13.3) 6 (5.3) 16 (14)
Treatment failure, n (%)
 Early 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Late 72 (23.8) 22 (22.5) 31 (31.6) 19 (17.8) 3 (3.1)
  Day of failure, median (range) 21 (14, 28) 24.5 (14, 28) 21 (14, 28) 21 (14, 28) 14 (14, 21)
  Reinfection* 70 (23.1) 22 (22.5) 31 (31.6) 17 (15.9) 2 (2)
  Recrudescence 2 (0.66) 0 (0) 0 (0) 2 (1.9) 1 (1)
 Day 3 clearance,  % (95 % CI)a 99.7 (98.3–100) 99.1 (94.5–100) 100 (96.7–100) 100 (96.7–100) 100 (96.7–100)
ACPR,  % (95 % CI)b
  Uncorrected 76.2 (71–80.9) 77.6 (68–83.4) 68.4 (58.2–77.4) 82.2 (73.7–89) 96.9 (91.3–99.4)
  PCR-corrected 99.3 (97.6–99.9) 100 (96.3–100) 100 (96.3–100) 98.1 (93.4–100) 99 (94.5–100)
Kaplan–Meier survival rate  
on day 28, % (95 % CI)c
 Uncorrected 76.8 (72.1–81.5) 78.2 (70.2–86.3) 69 (59.9–78.1) 82.5 (75.4–89.7) 97.1 (93.9–100)
 PCR-corrected 99.3 (98.3–100) 100d 100d 98.0 (95.3–100) 99.0 (97.2–100)
Fig. 2 Uncorrected and PCR-corrected Kaplan–Meier cumulative survival rate, Malawi, 2014
Page 7 of 10Paczkowski et al. Malar J  (2016) 15:236 
Table 3 Participant characteristics at study enrollment in Machinga, Nkhotakota, and Karonga Districts, in Malawi, 2014, 
restricted to participants with parasitemia at enrollment <200,000 parasites/μL (n = 426)
All participants were eligible for enrollment based on initial parasitaemia (1000–200,000 parasites/μL); however, 26 (6.1 %) participants had parasitaemia higher than 
200,000 parasites/μL according to slide reviews done after study completion
* Significant difference between study arms (p < 0.05); † significant difference between study sites (p < 0.05)
a Insecticide-treated bed net;
b Asexual parasitaemia.
Characteristic AL ASAQ
Total (n = 321) Site Total (n = 105)
Machinga (n = 112) Nkhotakota (n = 104) Karonga (n = 105)
Age, months (median,  
range)*, †
31 (6, 58) 35 (7, 58) 27 (6, 57) 32 (6, 57) 38 (9, 59)
Male, n (%)* 170 (53) 67 (59.8) 46 (44) 57 (54.3) 43 (41)
Participant slept under ITN 
previous night, n (%)†, a
258 (82.2) 101 (91) 64 (64) 93 (90.3) 85 (85)
Weight (kg) (mean, SD) 11.3 (3.5) 11.9 (3.1) 11.3 (2.2) 10.7 (4.8) 11.6 (3.5)
Haemoglobin (g/dL) (mean, SD) 9.7 (2.4) 9.4 (3.2) 9.7 (1.8) 10.1 (1.6) 9.9 (1.8)
Anaemia (Hb ≤ 11.0 g/dL)† 250 (78) 99 (88.4) 78 (75) 73 (70) 79 (75.2)
Parasitaemia (parasites/μL) 
(geometric mean, range)b
3 1,888 (1098,  
198,789)
2 5,700 (1100,  
198,000)
3 2,860 (1393,  
198,789)
4 0,135 (2066,  
199,187)
2 5,952 (1019, 
197,701)
Table 4 Response to treatment over 28-day follow-up among participants with enrollment parasitemia <200,000 para-
sites/μL in a therapeutic efficacy study in Machinga, Nkhotakota, and Karonga Districts in Malawi, 2014 (n = 426)
* Significant difference between study sites (p < 0.05)
a Percent day 3 clearance was estimated only among participants still enrolled in the study on day 3
b Adequate clinical and parasitologic response (ACPR) was estimated only among participants who reached a valid study endpoint
c The Kaplan–Meier cumulative survival rate estimate included all study participants who contributed person-days during the 28-day follow-up
d For Kaplan–Meier cumulative survival rates of 100 %, confidence intervals were not estimated
Estimate AL ASAQ








Participants lost to follow-up, n (%) 33 (10.3) 14 (12.5) 14 (13.5) 5 (4.8) 15 (14.3)
Treatment failure, n (%)
 Early 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Late* 70 (24.3) 22 (22.5) 30 (33.3) 18 (18) 2 (2.2)
  Day of failure, median (range) 21 (14, 28) 24.5 (14, 28) 21 (14, 28) 21 (14, 28) 17.5 (14, 21)
  Reinfection* 68 (23.6) 22 (22.5) 30 (33.3) 16 (16) 1 (1.1)
  Recrudescence 2 (0.7) 0 (0) 0 (0) 2 (2) 1 (1.1)
 Day 3 clearance,  % (95 % CI)a 99.7 (97.5–100) 99.1 (94.5–100) 100 (96.5–100) 100 (96.6–100) 100 (96.6–100)
ACPR,  % (95 % CI)b
 Uncorrected 75.7 (70–80.5) 77.6 (68–83.4) 67.7 (56–76.3) 82 (73.1–89) 97.8 (92.2–99.7)
 PCR-corrected 99.3 (97.5–99.9) 100 (96.3–100) 100 (96–100) 98 (93–100) 99 (94–100)
Kaplan–Meier survival rate  
on day 28, % (95 % CI)c
 Uncorrected 76.3 (71.4–81.2) 78.2 (70.2–86.3) 67.4 (58–77.1) 82.2 (74.8–89.7) 97.9 (95–100)
 PCR-corrected 99.3 (98.3–100) 100d 100d 97.9 (94.9–100) 99.0 (96.9–100)
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either treatment were given rescue treatment. AEs during 
drug administration were infrequent in both arms, with a 
maximum of 5  % of patients reporting an AE on day 1, 
2, or 3. The most commonly reported AEs were cough, 
fever, and upper respiratory tract infection. There were a 
total of four SAEs. One participant in the ASAQ arm was 
treated with parenteral quinine on Day 1 for a worsening 
clinical picture. Unfortunately, blood was not drawn for a 
parasitaemia estimate. Three participants (two in AL arm 
and one in ASAQ arm) were hospitalized for treatment of 
pneumonia; none of these were thought to be caused by 
the study drug.
Liver function tests
Among ASAQ participants, the median day 0 ALT was 
42.3  U/L (range 6.4, 80.3  U/L) and the median AST 
was 50.6 U/L (range 21.2, 122.6  U/L) (Fig.  4). By day 7, 
median ALT levels decreased to 16.6  U/L (range: 6.5, 
65.7  U/L) and median AST to 37.1  U/L (range 17.6, 
106  U/L). The median differences between day 7 and 
day 0 were statistically significant for both ALT (median 
difference: −9.4  U/L, p =  0.009) and AST (median dif-
ference: −13.4 U/L; p = 0.002) levels (Fig. 4). No partic-
ipants had AST or ALT values more than 2.5 times the 
upper limit of normal at any time (normal range: ALT: 
0–50 U/L; AST: 0–60 U/L).
Discussion
Both AL and ASAQ remain highly efficacious and well 
tolerated treatments for uncomplicated P. falciparum 
malaria in children age 6–59 months in Malawi, with PCR-
corrected ACPRs well above the 90  % WHO threshold 
for both treatments, and high day 3 parasite clearance for 
both treatments. The uncorrected efficacy of AL was sig-
nificantly lower than that of ASAQ, with significant differ-
ences in the numbers of reinfections between sites. This is 
likely due to the shorter half-life of AL compared to ASAQ, 
resulting in a shorter period of post-treatment prophylaxis.
Overall, the corrected efficacies for both AL and ASAQ 
are consistent with findings from other studies conducted 
in Malawi and elsewhere in the region [3, 5, 11–13]. In a 
therapeutic efficacy study conducted in 2010 in six study 
sites across Malawi, the combined PCR-corrected ACPR 
for AL was 93.4 % [3]. While the earlier study in Malawi 
detected five ETFs compared to zero in this study, day 3 
parasite clearance was 99.1 %, comparable to the 99.7 % 
clearance reported here. Taken together, the results from 
the 2010 study and this study are suggestive of contin-
ued, high efficacy of AL. Although there are no previ-
ously published reports of ASAQ efficacy in Malawi, 
results reported here are in line with studies of ASAQ 
in children 6–59  months from neighbouring countries, 
including Mozambique, Uganda, Kenya, and Madagas-
car, which have reported efficacy from 90 to 99.6  % [5, 
11–14].
Fig. 3 Day 0, day 14, and day 28 mean haemoglobin (Hb) levels 
among participants randomized to AL and ASAQ, Malawi, 2014
Fig. 4 Aspartate transaminase (AST)* and alanine transaminase (ALT)* levels on day 0 and day 7 among participants randomized to ASAQ†, Malawi, 
2014. *Normal range: ALT: 0–50 U/L; AST: 0–60 U/L. †ALT and AST data at both time points available for 28 and 30 participants, respectively. ALT: Day 
0 median 42.3 U/L (range: 6.4 U/L, 80.3 U/L; Interquartile range (IQR): 15 U/L, 53.2 U/L); Day 7 median 16.6 U/L (range: 6.5 U/L, 65.7 U/L; IQR: 12.1 
U/L, 40.6 U/L); median difference between day 0 and day 7: −9.4 U/L, p = 0.009. AST: Day 0 median 50.6 U/L (range: 21.2 U/L, 122.6 U/L; IQR: 38.8 
U/L, 61.9 U/L); Day 7, median 37.1 U/L (range: 17.6 U/L, 106 U/L; IQR: 27.9 U/L, 48.7 U/L); median difference between day 0 and day 7: −13.4 U/L; 
p = 0.002. No participants had AST or ALT values more than 2.5 times the upper limit of normal at any time
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The lower uncorrected efficacy in the AL arm can likely 
be explained in part by the shorter half-life of lumefan-
trine (3–6  days) compared to amodiaquine (6–18  days) 
[15, 16]. In addition, the recent preferential use of AL 
over ASAQ may have selected for parasites with greater 
resistance to AL. Although testing for molecular mark-
ers of resistance was not performed in this study, a recent 
study in Uganda also found a significantly higher rate of 
reinfections in children treated with ASAQ compared 
to AL, with a greater proportion of isolates demonstrat-
ing genetic polymorphisms consistent with resistance to 
ASAQ than to AL, suggesting that parasite susceptibility 
to the drugs may also be contributing [14].
While there were differences in uncorrected AL effi-
cacy between sites, these were not statistically significant. 
However, this study was not powered to detect differences 
by site, and these differences may have been significant 
in an appropriately powered study. Reinfections did dif-
fer by site, with significantly more reinfections in Nkho-
takota compared to the other sites. The higher number 
of reinfections might be related to lower reported use of 
ITNs among children sampled from Nkhotakota (64.2 %) 
compared to those from Machinga (91  %) and Karonga 
(89.1 %). Alternatively, the higher number of reinfections 
might reflect a higher transmission intensity in that study 
site, although malaria prevalence estimates from the 2014 
Malaria Indicator Survey did not show large differences 
between sites (36 % for Nkhotakota, 33 % for Machinga, 
and 29 % for Karonga) [2]. This suggests a need for con-
tinued implementation and expansion of malaria control 
measures across Malawi.
As expected, haemoglobin levels among children ran-
domized to both treatments improved significantly over 
the 28-day follow-up. Both AL and ASAQ were well-
tolerated and safe, as has been previously reported [12, 
17–19]. There were no drug related SAEs. There was no 
evidence for drug related liver toxicity in patients taking 
ASAQ. In fact, the median AST and ALT were both sig-
nificantly lower at day 7 than at enrollment. Prevalence 
of vomiting following treatment was similar to findings 
from other studies in the region, finding that 0–8.3  % 
vomited following AL treatment and 2.1–10.6 % vomited 
following ASAQ [5, 20–22].
This therapeutic efficacy study had several limitations. 
First, several participants with a final parasitaemia greater 
than 200,000 parasites/μl were included, as these patients 
were deemed eligible according to the initial microscopy 
reading. Treating these participants with AL or ASAQ 
could have increased the risk of delayed parasite clearance 
and recrudescence as parasite biomass might be too high 
to be adequately cleared [23]. Reassuringly, none of these 
participants showed delayed parasite clearance nor had 
recrudescent infections, and the study results were not 
affected by removal of these participants from the analysis. 
Secondly, the evening dose of AL was not supervised, due 
to limited resources. Parents were asked at the visit the fol-
lowing morning whether the previous evening’s dose had 
been taken by the child. All parents reported having admin-
istered the dose. This was additionally verified by having 
the parents return with the empty medication packaging. 
While it is possible that some parents incorrectly reported 
having given the dose, the very high efficacy found for 
AL suggests that this did not significantly affect the study 
results. Parental self-report of the second dose in lieu of 
direct observation has been used in other studies, with no 
significant effect on study outcomes noted [24]. As missed 
evening doses would increase the risk of recrudescence, the 
true efficacy of AL would be higher than reported here if 
a significant number of evening doses were missed. Finally, 
the study included only 28 days of follow-up, the minimum 
recommended by WHO for drugs with elimination half-
lives of less than 7 days; any additional recurrences beyond 
this time frame were not captured.
The results of this study demonstrate that AL and 
ASAQ remain efficacious treatments for uncomplicated 
P. falciparum malaria in Malawi. There is no evidence at 
this time that a change in regimens is warranted. How-
ever, continued monitoring of drug efficacy, following 
WHO recommendations, is needed. Finally, the relatively 
high reinfection rates observed during the study period 
are evidence of the continued need to scale-up the own-
ership and use of effective malaria prevention interven-
tions, such as ITNs.
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